TRACON Pharmaceuticals (NASDAQ:TCON) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Performance

TRACON Pharmaceuticals stock opened at $0.03 on Friday. The stock has a 50-day simple moving average of $0.08 and a 200 day simple moving average of $0.50. The stock has a market capitalization of $89,001.00, a P/E ratio of 0.01 and a beta of 1.43. TRACON Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $14.75.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.